News | Solas BioVentures

top of page

2020

Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers

November 11, 2020

Knopp BioSciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

SEPTEMBER 16, 2020

Solas BioVentures Announces the Addition of Scott Rader to its Team

JULY 15, 2020

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

JULY 15, 2020

Cryosa Completes $8.25 Million in Series A-2 Funding for Further Development of Breakthrough, Minimally Invasive Treatment for Obstructive Sleep Apnea

JUNE 25, 2020

Francis Medical Announces First Patient Enrolled in VAPOR 1 IDE Study
for Water Vapor Ablation of Prostate Cancer

JUNE 9, 2020

Baebies Announces CE Mark for Newborn Screening Assays for Galactosemia and Biotinidase Deficiency on SEEKER

MAY 27, 2020

Baebies Announces Submission of 510(k) to U.S. FDA for Glucose-6-Phosphate Dehydrogenase on FINDER

MAY 7, 2020

AEGEA Medical Receives FDA Approval for and Performs First Commercial Cases With the Mara™ Water Vapor Ablation System

MAR 24, 2020

BioStable Science & Engineering Announces Initial Closing of Series C Equity Round

FEB 25, 2020

Jerome Edwards of CardioNXT Presents on the Main Stage at the JP Morgan and Piper Sandler (formerly Piper Jaffray) Annual Healthcare Conferences

JAN 14, 2020

bottom of page